USITC judge finds Glas infringes 12 JUUL patent claims, proposes import limit

A USITC administrative law judge on 20 October 2026 preliminarily found that Glas devices, cartridges and components infringe 12 claims across two JUUL patents, and recommended a limited exclusion order. The recommendation is not yet a Commission order.

An import bar is recommended but not in force

The judge, Doris Johnson Hines, found a violation of section 337 of the Tariff Act of 1930 in investigation 337-TA-1464, according to the initial determination notice. She proposed a limited exclusion order covering products the two Glas entities import, intend to import or sell after import.

A cease and desist order is also recommended. Both measures still require Commission action; the USITC notice published in the Federal Register on 27 October 2026 opens a public-interest comment window rather than imposing a remedy.

Which claims survived and which did not

Five further claims were not proved infringed, so the finding covers 12 of the 17 claims at issue.

The judge also rejected Glas’s argument that the asserted claims are invalid, and held that both patents satisfy the technical prong of the domestic industry requirement. The economic prong was handled separately: the judge granted JUUL summary judgment on it on 27 May 2026, and the Commission extended its deadline for deciding whether to review that ruling to 9 July 2026.

FDA authorisation does not settle import rights

Glas obtained marketing authorisation for four pods through the PMTA route on 5 May 2026, roughly five months before the patent ruling.

FDA described the decision at the time as its first marketing authorisation for non-tobacco, non-menthol ENDS products. The pods belong to the G² system; FDA had already authorised the G² rechargeable device and a Blonde Tobacco pod.

G² pairs with a phone app that verifies a government-issued ID over Bluetooth and runs periodic biometric checks. FDA technical review documents state the device locks after a grace period of about one hour once it loses contact with the verified phone. Cartridge encryption ties the device to authenticated Glas pods.

Those FDA permissions cover named Glas products and carry no third-party patent licence. The publicly released two-page initial determination does not give a claim-by-claim technical comparison, and the notice leaves open which of the FDA-authorised G² devices and pods fall inside the proposed exclusion.

Who is affected while the Commission decides

Glas’s US supply chain faces the nearest exposure, but the size of that exposure depends on scope the Commission has not fixed. Distributors and retailers carrying G² hardware and the four authorised pods have no confirmed product list to work from; the exclusion, if issued, would bite at import and on post-import sales.

The Commission’s public-interest questions ask commenters about effects on US public health, competition, domestic production of like products and consumers. It also asks whether substitute products exist and whether JUUL, its licensees or other suppliers could meet demand within a commercially reasonable time.

JUUL Labs and VMR Products filed the complaint on 30 September 2025 and supplemented it four times that November and December, according to the USITC institution notice. The Commission voted to institute on 16 December 2025 and published the notice on 19 December 2025. That institution notice states that remedial orders in section 337 cases take effect when issued and become final 60 days later unless the US Trade Representative disapproves them for policy reasons.

VapeBrief’s calculation: the exclusion request was filed about seven months before FDA’s 5 May 2026 authorisation and about twelve and a half months before the 20 October 2026 initial determination. Neither gap changes the legal tests, which run on separate tracks.

Comments close on 19 November

Submissions on the public interest are due 19 November 2026, and the Commission will then decide whether to review the initial determination and what remedy, if any, to order. Until a final order issues, Glas’s FDA-authorised pods remain authorised for marketing; import treatment is unresolved.

Questions readers ask

Are Glas's FDA-authorised pods banned from import yet?

No. The 20 October 2026 finding and the recommended exclusion order are preliminary; the USITC Commission must still decide on review and remedy, and the public-interest comment period closes on 19 November 2026.

Does FDA marketing authorisation protect Glas from the patent case?

No. FDA authorisation covers marketing eligibility for named products and, as the FDA materials cited in the case indicate, does not grant a third-party patent licence. The section 337 case addresses import and sale of products found to infringe.